Harbour BioMed Welcomes Dr. Raymond Zheng as CBO
Harbour BioMed, a global biopharmaceutical firm dedicated to revolutionary antibody therapeutics in oncology and immunology, proudly introduces Dr. Raymond Zheng as its new Chief Business Officer (CBO). Dr. Zheng will contribute to the company's ambition of developing ground-breaking treatments by overseeing global business development and alliance management. This strategic appointment is timely as Harbour BioMed pursues its long-term goals and strengthens its innovative portfolio.
Dr. Zheng's Vision and Leadership
Dr. Zheng is set to maximize Harbour BioMed’s diverse product portfolio through effective partnerships and resource optimization. His leadership aims to forge strong alliances, enhancing the company's ability to meet key medical needs. This commitment is crucial for reinforcing and extending Harbour BioMed's reach in under-served markets.
His Experience in the Biopharmaceutical Field
With a solid foundation in science, Dr. Zheng completed a research fellowship in translational oncology at Harvard Medical School prior to entering the biopharmaceutical realm. He previously founded Urica Therapeutics, where he led clinical development for an innovative gout therapy. His experience also includes significant roles at Fortress Biotech and Agenus, focusing on business development and transformative partnerships.
Comments from Leadership
Dr. Jingsong Wang, Founder and CEO of Harbour BioMed, expressed enthusiasm about Dr. Zheng’s appointment, highlighting that his strategic insights will accelerate the company’s growth in immune-oncology and related therapeutic areas. Underlining the importance of collaboration, Dr. Wang emphasized the role of Dr. Zheng in enhancing the company's value proposition.
Dr. Zheng’s Commitment to Innovation
Dr. Zheng shared his excitement about joining Harbour BioMed, expressing a commitment to pushing the frontiers of medicinal product development. He recognizes the potential of the Harbour Mice® platform in producing leading-edge antibody therapies recognized globally. His goal is to foster partnerships that will not only boost the company’s impact but also enhance innovative solutions in the biopharmaceutical sector.
Overview of Harbour BioMed
Harbour BioMed is dedicated to discovering, developing, and commercializing unique antibody therapeutics with a focus on immunology and oncology. Building a diverse pipeline through robust research and development and strategic partnerships, the company strives to address significant healthcare demands while setting new benchmarks in therapeutics.
Proprietary Technology and Advancements
The proprietary Harbour Mice® platform produces fully human monoclonal antibodies in varied formats. By integrating advanced techniques like the HCAb-based immune cell engagers (HBICE®), Harbour BioMed aims to achieve efficacious and innovative treatments, paving the way for future therapeutic advancements.
Frequently Asked Questions
1. What role will Dr. Raymond Zheng play at Harbour BioMed?
Dr. Zheng will serve as Chief Business Officer, overseeing global business development and partnership management, aiming to enhance the company’s strategic goals.
2. What is the Harbour Mice® platform?
The Harbour Mice® platform generates fully human monoclonal antibodies, providing unique solutions in the field of antibody therapeutics.
3. What is Harbour BioMed's focus area?
The company is focused on developing innovative therapeutic antibodies primarily in oncology and immunology.
4. What are HBICE® technologies?
HBICE® refers to HCAb-based immune cell engagers that deliver enhanced tumor-killing effects, surpassing traditional therapies.
5. What is the mission of Harbour BioMed?
Harbour BioMed is committed to addressing key medical needs by developing cutting-edge therapies, built on a foundation of strong collaborations and technological innovations.
